Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

31 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcription profiling of mouse CD4+ GFP- (Teff) and CD4+ GFP+ (Treg) T cells treated with IL-2

ABSTRACT: To obtain the molecular signature of the effect that the IL-2 therapeutic dose induces on T cells in vivo, we performed gene array analysis. Since it was critical to perform this analysis on highly purified Tregs and Teffs, and also because activated Teffs can acquire CD25 expression, we used GFP-Foxp3 knock-in mice which allow for the purification of Tregs and Teffs based on the GFP expression. Illumina gene array was carried out on FACS sorted CD4+ GFP+ (Tregs) and CD4+ GFP- (Teffs) of mice that received either PBS or the curative schedule of IL-2, 2 hours after the last injection.

Further raw data files are available on the FTP site for this experiment.

ORGANISM(S): Mus musculus

SUBMITTER: Nicolas Cagnard

PROVIDER: E-MEXP-2530 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Transcription profiling by array of mouse CD4+ GFP+ (tregs) and CD4+ GFP- (Teffs) cells treated with IL-2

Project description:To obtain the molecular signature of the effect that the IL-2 therapeutic dose induces on T cells in vivo, we performed gene array analysis. Since it was critical to perform this analysis on highly purified Tregs and Teffs, and also because activated Teffs can acquire CD25 expression, we used GFP-Foxp3 knock-in mice which allow for the purification of Tregs and Teffs based on the GFP expression. Illumina gene array was carried out on FACS sorted CD4+ GFP+ (Tregs) and CD4+ GFP- (Teffs) of mice that received either PBS or the curative schedule of IL-2, 2 hours after the last injection.

2011-03-21 | E-MEXP-2689 | biostudies-arrayexpress

S6K_RiBi

Project description:Transcriptional analysis of concequent lack of rpS6 kinase activity in mice livers hepatocytes due to deletion of S6 kinases 1 and 2 (S6K1 and S6K2).

2013-01-16 | E-MEXP-3518 | biostudies-arrayexpress

OJeanJean_eRF3a_ATF4

Project description:We previously showed that eRF3a depletion in the human colon carcinoma cell line HCT116 p53+/+ induces mTOR signaling pathway inhibition (Chauvin et al., 2007) suggesting that eRF3a belongs to a regulatory mechanism that modulate mTOR activity. However, this mechanism and the precise role of eRF3a remain to be determined. Here, to elucidate the mechanism dictating mTOR signaling pathway inhibition, we aimed to define the transcript expression and polysome profiles of HCT116 cells after short interfering RNA (siRNA)-mediated depletion of eRF3a. Three days after HCT116 cells electroporation with either sh-3a1 which was previously shown for effectively silence eRF3a (Chauvin et al., 2005) or control shRNA (sh-Ctrl), total and polysome-associated RNAs were extracted and we conducted a microarray analysis of differentially expressed genes using the Illumina HumanHT-12 Expression BeadChips.

2012-08-30 | E-MEXP-3512 | biostudies-arrayexpress

Transcription profiling of human brain tissue from an individual with neurological disease

Project description:Transcriptomic comparison of brain tissues

2010-11-25 | E-TABM-888 | biostudies-arrayexpress

Eliane_IL2.Rapa bis

Project description:Administration of low-dose IL-2 prevents and cures type 1 diabetes (T1D) in NOD mice by boosting pancreatic regulatory T cells (Tregs) and is currently being evaluated in humans. Here, to improve treatment efficacy we tested higher IL-2 doses that, despite further boosting Tregs, rapidly precipitated T1D in pre-diabetic mice due to generalized immune activation. Although the combination of rapamycin (RAPA) plus IL-2 prevents NOD T1D development, a recent clinical trial translating this strategy into patients was halted due to C-peptide decline. Here, we show that RAPA/IL-2 combination was also ineffective to cure new onset T1D in mice and, surprisingly, RAPA broke IL-2-induced tolerance in a reversible way. RAPA partially counteracted IL-2 effects on Tregs and the combined treatment unexpectedly, impaired glucose homeostasis at multiple levels, possibly explaining the clinical outcome. Our data help understand IL-2 alone or RAPA/IL-2 combination limitations and could lead to the design of improved T1D therapies.

2013-12-10 | E-MEXP-3789 | biostudies-arrayexpress

Foie WTS vs WT

Project description:Transcriptional and polysomal analysis of mice liver hepatocytes after 4-hour refeeding as compared to overnight starved controls.

2013-01-24 | E-MEXP-3522 | biostudies-arrayexpress

siRNA profiling of human synovial fibroblasts depleted for clusterin

Project description:Analysis of synoviocytes cell form patients suffering of Rheumatoid arthritis and depleted for clusterin by siRNA knockdown. Note: this experiment was reloaded into ArrayExpress on 2nd December 2009 because the incorrect array design had originally been selected. The identifiers in the datafile were also fixed to match the array design.

2009-12-04 | E-TABM-653 | biostudies-arrayexpress

Heterogeneous CD3 expression levels in differing T-cell subsets account for in vivo anti-CD3-mediated immune resetting

Project description:The tolerogenic anti-CD3 monoclonal antibodies (anti-CD3) are promising compounds for the treatment of type 1 diabetes (T1D). Anti-CD3 administration induces transient T-cell depletion both in preclinical and in clinical studies. Notably, said depletion mainly affects CD4+ but not CD8+ T cells. Moreover, T1D reversal in preclinical models is accompanied by the selective expansion of CD4+FOXP3+ T regulatory (Treg) cells, which are fundamental for the long-term maintenance of anti-CD3-mediated tolerance. The mechanisms that lead to this immune-shaping by affecting mainly CD4+ T effector cells while sparing CD4+FOXP3+ Treg cells have still to be fully elucidated. This study shows that CD3 expression levels differ from one T-cell subset to another. CD4+FOXP3- T cells contain higher amounts of CD3 molecules than do CD4+FOXP3+ and CD8+ T cells both in mice and in humans. Said differences may explain the anti-CD3-mediated immune resetting that occurs in vivo after anti-CD3 administration in mice. In addition, transcriptome analysis demonstrates that CD4+FoxP3+ Treg cells are significantly less responsive than CD4+FoxP3- T cells to anti-CD3 treatment at molecular levels. Thus, heterogeneity in CD3 expression likely confers the various T-cell subsets differing susceptibility to in vivo tolerogenic anti-CD3-mediated modulation. This data sheds new light on the molecular mechanism that underlies anti-CD3-mediated immune resetting, and thus may open new opportunities to improve this promising treatment.

2015-01-19 | E-MTAB-2437 | biostudies-arrayexpress

Transcription profiling of rat kidney and liver from several different strains to determine the effects of hyperglycaemia and genetic background difference on gene expression

Project description:Effects of hyperglycaemia and genetic background differences on renal and hepatic gene expression

2009-06-03 | E-TABM-502 | biostudies-arrayexpress

Transcription profiling of hepatocytes from mice that are hyperglycaemic, obese and insulin resistant as a result of being fed a high fat diet - Illumina dataset

Project description:Effect of high fat diet feeding on gene expression

2009-09-15 | E-TABM-548 | biostudies-arrayexpress